Caring for children and their health has been a mainstay of Johnson & Johnson’s 130-year history.
Our commitment to children and their well-being continues today. As a company, we work to improve the health and lives of children globally. Our dedicated Child Health Innovation Leadership Department, or CHILD, was created with this focus in mind. As part of the Office of the Chief Medical Officer (OCMO), CHILD brings scientific excellence, bioethics and values-driven decision-making to children’s healthcare.
Today, approximately 50% of all medicines used to treat children do not have in their labels the necessary information needed to guide appropriate use in children. In neonates, that number is approximately 90%. One of the reasons is that clinical trials for children are challenging to design and conduct. It can be difficult and time-consuming to recruit participants and assess study endpoints. Consequently, participation in clinical trials designed to research new medicines for children is not a high priority for many medical institutions. As a result, child-centric medical innovation has lagged behind adults.
Johnson & Johnson aims to change this dynamic. Our CHILD team’s deep pediatric expertise complements our research and development team knowledge across all of our sectors, including pharmaceutical, medical devices and consumer products. Our experts provide advice on the design of clinical studies across all therapeutic areas and functions of our organization with a special focus on the needs of pediatric patients. This collaboration incorporates the best interests of children into all decision-making and ensures all of our operations are applied in a child-centered way.
Our work doesn’t end there. Johnson & Johnson is leading industry, regulatory and academic groups to drive the creation of new policies focused on medical treatments for children. We are a founding member of the Institute for Advanced Clinical Trials (I-ACT) for Children, a nonprofit organization that will operate the first globally collaborative pediatric clinical trial network.
Our experts lead high-impact collaborations across the industry, breaking down barriers to investing meaningfully in child health and wellness. Johnson & Johnson leaders worked closely with the Innovations Medicines Initiative to form a pan-European Pediatric Clinical Trial Network and work to harmonize regulatory guidelines globally.
Children’s physiology is unique, and child-centric innovation and therapies are necessary to achieve better outcomes in children. Our dedication to understanding children’s health will help lead to a paradigm shift to uphold the safety and effectiveness of pediatric treatments.